Novo Nordisk A/S raised its forecasts for the second time this year on a rosy outlook for its obesity and diabetes drugs, though the its US shares fell as sales of the new Wegovy weight-loss pill failed to top analysts’ expectations.
Novo Nordisk A/S raised its forecasts for the second time this year on a rosy outlook for its obesity and diabetes drugs, though the its US shares fell as sales of the new Wegovy weight-loss pill failed to top analysts’ expectations.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)